Hongbo Lu
QuietNamed in filings at Vivo InnovationOn the current fund
- Board seats filed
- 7
Named in filings at Vivo InnovationOn the current fund
all filings on record
last 24 months
from a verified or cited source
| BlossomHill Therapeutics | Biotech & pharma | December 2023 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis |
| Zenas BioPharma (Cayman) | Biotech & pharma | November 2022 | Longitude 103.8 East, Longitude Capital, Longitude Prime |
| Perfuse Therapeutics | Biotech & pharma | July 2020 | Hatteras Venture Partners |
| ADARx Pharmaceuticals | Biotech & pharma | July 2020 | Bain Capital Life Sciences, Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, TCG Crossover, Tcgx Asia Life Sciences |
| Rgenta Therapeutics | Biotech & pharma | January 2020 | None on file |
| TP Therapeutics | Biotech & pharma | October 2018 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis, Venbio Global Strategic, Venbio Select |
| AVEDRO | Medical devices | April 2018 | Abingworth Bioventures, Aperture, Borealis, Caduceus Capital, Healthquest Partners, Orbimed Asia Partners, Orbimed Genesis, Sofinnova Venture Partners |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Hongbo Lu on the board, based on 7 filed seats with a verified or cited source.